Recombinant human platelet-derived growth factor for refractory nondiabetic ulcers: a retrospective series.
BACKGROUND
Recombinant human platelet-derived growth factor-BB (rhPDGF-BB or rhPDGF gel 0.01%) has been approved by the U.S. Food and Drug Administration (FDA) for topical use on lower extremity, neuropathic, diabetic ulcers to enhance healing and has been reported to be effective in expediting the healing of full-thickness chronic pressure ulcers. Published clinical data using rhPDGF gel to treat nondiabetic and nonpressure-related ulcers have been limited.


OBJECTIVE
To determine the effectiveness of topical rhPDGF gel in treating refractory chronic ulcers other than diabetic, neuropathic ulcers.


METHODS
A retrospective chart review was performed on patients without diabetes mellitus-related ulcers treated with topical rhPDGF gel 0.01%.


RESULTS
Twelve patients with 14 ulcers were treated. Nine of 14 ulcers healed (64%) with a mean time to healing of 26 weeks. Two of the nine healed ulcers (22%) reopened during a 15-month follow-up period.


CONCLUSIONS
rhPDGF gel is an effective and well-tolerated treatment for refractory chronic ulcers.
Harrison-Balestra
Catherine
C
Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida 33136, USA.
Eaglstein
William H
WH
Falabela
Anna F
AF
Kirsner
Robert S
RS
D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
D010982:Platelet-Derived Growth Factor; D011994:Recombinant Proteins